KR20180019839A - Composition for Enhancing Immune System Function Comprising Extract of Protaetia Orientalis Larva and Red Ginseng - Google Patents
Composition for Enhancing Immune System Function Comprising Extract of Protaetia Orientalis Larva and Red Ginseng Download PDFInfo
- Publication number
- KR20180019839A KR20180019839A KR1020160104039A KR20160104039A KR20180019839A KR 20180019839 A KR20180019839 A KR 20180019839A KR 1020160104039 A KR1020160104039 A KR 1020160104039A KR 20160104039 A KR20160104039 A KR 20160104039A KR 20180019839 A KR20180019839 A KR 20180019839A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- larva
- white spotted
- larvae
- red ginseng
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 41
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 11
- 241000083618 Protaetia orientalis Species 0.000 title abstract 5
- 210000000987 immune system Anatomy 0.000 title description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 30
- 230000032683 aging Effects 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 238000007654 immersion Methods 0.000 claims abstract description 9
- 239000000052 vinegar Substances 0.000 claims description 27
- 235000021419 vinegar Nutrition 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 15
- 241000239290 Araneae Species 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 7
- 235000013339 cereals Nutrition 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 230000002434 immunopotentiative effect Effects 0.000 claims description 3
- 230000036039 immunity Effects 0.000 abstract description 19
- 235000013305 food Nutrition 0.000 abstract description 11
- 231100000419 toxicity Toxicity 0.000 abstract description 10
- 230000001988 toxicity Effects 0.000 abstract description 10
- 238000001035 drying Methods 0.000 abstract description 5
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 230000035943 smell Effects 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 19
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 16
- -1 polyoxyethylene Polymers 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 12
- 229940027941 immunoglobulin g Drugs 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 244000024873 Mentha crispa Species 0.000 description 8
- 235000014749 Mentha crispa Nutrition 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000029662 T-helper 1 type immune response Effects 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000029069 type 2 immune response Effects 0.000 description 5
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 229960004106 citric acid Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229940028885 interleukin-4 Drugs 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 235000019629 palatability Nutrition 0.000 description 3
- 229940101267 panthenol Drugs 0.000 description 3
- 239000011619 pantothenol Substances 0.000 description 3
- 235000020957 pantothenol Nutrition 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 229960001790 sodium citrate Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- OXXDGKNPRNPMLS-UHFFFAOYSA-N 2-Hydroxy-3-methyl-4H-pyran-4-one Natural products CC1=C(O)OC=CC1=O OXXDGKNPRNPMLS-UHFFFAOYSA-N 0.000 description 1
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 1
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000413 sensory ganglia Anatomy 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12J—VINEGAR; PREPARATION OR PURIFICATION THEREOF
- C12J1/00—Vinegar; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/10—Drying, dehydrating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/50—Concentrating, enriching or enhancing in functional factors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Botany (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 흰점박이꽃무지 유충 및 홍삼 추출물을 유효성분으로 하는 면역 강화 조성물에 관한 것으로, 보다 상세하게는 흰점박이꽃무지 유충을 아세트산이 포함된 침지액에 침지하여 숙성한 이후, 건조하여 제조한 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 유효성분으로 포함하는 조성물에 관한 것이다.
The present invention relates to an immunopotentiating composition comprising a white spotted flower larva and a red ginseng extract as an active ingredient. More particularly, the present invention relates to an immunopotentiating composition comprising a white spotted flower larva and a red ginseng extract as active ingredients, White spotted moth larvae extract and red ginseng extract as an active ingredient.
홍삼은 수삼(땅에서 캐어내 말리지 않은 상태의 인삼)을 증숙한 후 건조하여 제조한 것으로, 열을 가하기 때문에 입체적인 화학변화를 받아 수삼 표피의 색이 붉게 되기 때문에 홍삼이라 불린다. 이러한 증숙 과정을 거친 홍삼은 수삼에서는 발견되지 않은 특유성분인 3-hydroxy-2-methyl-4-pyrone(Maltol)이 생성된다. 홍삼 사포닌 중 ginsenoside Rb1 은 진정작용, 용혈방어작용, 중추신경억제, 해열진통, 간 기능 보호 기능이 있으며, 지각신경절에서 신경성장 인자의 신경돌기 성장을 촉진한다고 한다. 또한 ginsenoside Rg1 에는 피로회복 촉진작용, 학습기능개선, 항피로 작용을 하고 있으며, ginsenoside Rb2, Re, Rg1은 항당뇨, 항동백경화, 간세포 증식, 골수세포 합성 촉진작용, 단백생합성, 지질생합성을 촉진시킨다고 보고되어 있다. Red ginseng is made by boiling ginseng (ginseng that is not dried in the ground) and then drying it. It is called red ginseng because the color of red ginseng skin gets red due to three-dimensional chemical change because it applies heat. The red ginseng thus obtained is 3-hydroxy-2-methyl-4-pyrone (Maltol), a unique ingredient not found in ginseng. Ginsenoside Rb1 in red ginseng saponins has sedative, hemolytic defense, central nervous system inhibition, antipyretic analgesic and hepatic function protection and promotes neurite growth of nerve growth factor in the sensory ganglia. In addition, ginsenoside Rg1 promotes fatigue recovery, improves learning and anti-fatigue, and ginsenoside Rb2, Re, and Rg1 promote antidiabetic, anti-oxidant, hepatocyte proliferation, promoting bone marrow cell synthesis, protein biosynthesis and lipid biosynthesis Reported.
한편, 면역(Immune)이란 인간 및 동물의 체내에서 외래성 및 내인성 이물질을 생리적으로 인식하여 배제하고, 항상성을 유지하기 위한 기작을 일컫는다. 면역은 크게 두 가지로 분류할 수 있는데, 태어날 때부터 지니고 있는 선천면역(innate immunity)과 후천적으로 생활 등에 적응되어 얻어지는 획득면역(acquired immunity)으로 구분된다.On the other hand, immune refers to a mechanism for physiologically recognizing and excluding exogenous and endogenous foreign substances in human and animal body, and maintaining homeostasis. Immunity can be categorized into two broad categories: innate immunity from birth, and acquired immunity acquired through adaptation to life and the like.
이 중 획득면역은 후천면역이라고도 하는데, 처음 침입한 항원에 대해 기억할 수 있고, 다시 침입할 때 특이적으로 반응하여 효과적으로 항원을 제거할 수 있으며, 선천면역을 보강하는 역할을 한다.Acquired immunity is also referred to as acquired immunity. It can remember about the first invaded antigen, reacts specifically when invading again, effectively removes the antigen, and reinforces innate immunity.
획득면역에는 T세포와 B세포가 있는데, 가슴샘의 상피세포에서 특수한 내부 환경과 흉선의 액성인자에 의해 림프구로 분화하는 세포를 T세포라 하며, 가슴샘과 는 독립되어 골수에서 림프구로 분화하는 세포를 B세포라 한다.Acquired immunity includes T cells and B cells. The cells that differentiate into lymphocytes by the specific internal environment and thymus lytic factors in the thymus epithelium are called T cells, and the cells that differentiate from the bone marrow into lymphocytes, independent of the thymus, are called B Cell.
T세포의 역할은 B세포에 항체생산 자극을 주고 종양 세포 등의 항원을 직접 공격하는 것이며, B세포의 역할은 항원자극 및 T세포를 매개로 한 자극에 따라 항체생산세포로 성숙하여 IgM, IgG, IgA, IgE의 항체를 생산하고 분비하는 것이다.The role of T cells is to induce antibody production to B cells and to directly attack antigens such as tumor cells. The role of B cells matures into antibody-producing cells following antigen stimulation and T cell-mediated stimulation, and IgM, IgG , IgA, and IgE antibodies.
홍삼의 면역력 강화 효과에 대해서는 다수의 문헌이 공개되어 있는 실정이고, 흰점박이꽃무지 유충의 경우는 KR 특허출원번호 제10-2012-0066121호(발명의 명칭 : 흰점박이꽃무지를 유효성분으로 포함하는 염증성 질환의 예방 및 치료용 조성물)에서 흰점박이꽃무지를 유효성분으로 포함하는 염증성 질환의 예방 및 개선용 식품 조성물 및 제조방법에 대해 개시하고 있다.Many studies have been made on the effect of enhancing the immunity of red ginseng. In the case of the white spider mite larvae, KR Patent Application No. 10-2012-0066121 (title of invention: white spearmint flower as an active ingredient) A composition for preventing and treating an inflammatory disease, comprising a white spearmint flower as an active ingredient in a composition for preventing and treating an inflammatory disease.
그러나 홍삼 추출물 및 흰점박이꽃무지 유충 추출물을 모두 포함하는 면역력 강화 조성물에 대해서는 개시되지 않고 있다.
However, no immunosuppressive composition including both red ginseng extract and white spotted flower larva extract has been disclosed.
본 명세서 전체에 걸쳐 다수의 논문 및 특허문헌이 참조되고 그 인용이 표시되어 있다. 인용된 논문 및 특허문헌의 개시 내용은 그 전체로서 본 명세서에 참조로 삽입되어 본 발명이 속하는 기술 분야의 수준 및 본 발명의 내용이 보다 명확하게 설명된다.
Numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated herein by reference in their entirety to better understand the state of the art to which the present invention pertains and the content of the present invention.
본 발명의 발명자들은 흰점박이꽃무지 유충 특유의 이취를 제거하여 흰점박이꽃무지 유충의 식품 사용 가능성을 높일 수 있는 것은 물론, 흰점박이꽃무지 유충 고유의 독성은 없애고, 면역력 강화 효과는 높일 수 있는 흰점박이꽃무지 유충 추출물을 개발하기 위해 예의 연구 노력하였다. 그 결과, 흰점박이꽃무지 유충을 양조식초에 침지하여 5일 이상의 숙성 과정을 거쳐 흰점박이꽃무지 유충 추출물을 제조한 후 홍삼 추출물과 일정 비율로 혼합할 경우 흰점박이꽃무지 유충 특유의 이취 및 독성을 제거할 수 있는 것은 물론, 면역력 강화 측면에서 시너지 효과를 발생시킬 수 있다는 사실을 발견하여 본 발명을 완성하였다.The inventors of the present invention have found that it is possible not only to increase the possibility of using food of the white spearmint flower larvae by removing the unique odor of the white spotted spearmint flower larvae but also to eliminate the inherent toxicity of the white spotted spearmint larvae and to enhance the immunity strengthening effect We tried to develop the white spotted larvae larvae extract. As a result, the white spotted flower larvae were immersed in the vinegar for 5 days or more, and then, when they were mixed with the red ginseng extract at a certain ratio, the odor and toxicity specific to the white spotted flower larva Can be removed, and synergistic effects can be generated in terms of immunity enhancement, thus completing the present invention.
따라서 본 발명의 목적은 흰점박이꽃무지 유충 및 홍삼 추출물을 유효성분으로 하는 면역 강화 조성물을 제공하는데 있다.
Accordingly, an object of the present invention is to provide an immunity-enhancing composition comprising the white spotted moth larva and red ginseng extract as an active ingredient.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명, 청구범위 및 도면에 의해 보다 명확하게 된다.
Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.
본 발명은 면역 강화 조성물을 제공한다.The present invention provides immunoconjugation compositions.
본 발명의 발명자들은 흰점박이꽃무지 유충 특유의 이취를 제거하여 흰점박이꽃무지 유충의 식품 사용 가능성을 높일 수 있는 것은 물론, 흰점박이꽃무지 유충 고유의 독성은 없애고, 면역력 강화 효과는 높일 수 있는 흰점박이꽃무지 유충 추출물을 개발하기 위해 예의 연구 노력하였다. 그 결과, 흰점박이꽃무지 유충을 양조식초에 침지하여 5일 이상의 숙성 과정을 거쳐 흰점박이꽃무지 유충 추출물을 제조한 후 홍삼 추출물과 일정 비율로 혼합할 경우 흰점박이꽃무지 유충 특유의 이취 및 독성을 제거할 수 있는 것은 물론, 면역력 강화 측면에서 시너지 효과를 발생시킬 수 있다는 사실을 확인하였다.
The inventors of the present invention have found that it is possible not only to increase the possibility of using food of the white spearmint flower larvae by removing the unique odor of the white spotted spearmint flower larvae but also to eliminate the inherent toxicity of the white spotted spearmint larvae and to enhance the immunity strengthening effect We tried to develop the white spotted larvae larvae extract. As a result, the white spotted flower larvae were immersed in the vinegar for 5 days or more, and then, when they were mixed with the red ginseng extract at a certain ratio, the odor and toxicity specific to the white spotted flower larva As well as a synergistic effect in terms of enhancing immunity.
본 발명의 일 양태에 따르면, 본 발명은 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 유효성분으로 포함하되, 상기 흰점박이꽃무지 유충 추출물은 흰점박이꽃무지 유충을 아세트산이 포함된 침지액에 침지한 후 숙성하여 숙성된 유충을 제조한 후, 상기 숙성된 유충을 건조 및 분쇄하여 제조되는 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 포함하는 면역 강화 조성물을 제공한다.According to one aspect of the present invention, the present invention provides a method for preparing a white spotted moth larva, comprising the step of spraying a white spotted moth larva with an acetic acid in an immersion liquid containing white spotted moth larvae extract and red ginseng extract as an active ingredient, The present invention provides an immunity enhancing composition comprising a white spotted flower larva extract and a red ginseng extract prepared by aging the larvae to prepare aged larvae and then drying and pulverizing the aged larvae.
본 명세서에서 사용하는 용어‘흰점박이꽃무지 유충’은 딱정벌레목 꽃무지과에 속하는 곤충의 유충을 의미할 수 있다.As used herein, the term " white spotted flower larvae " may mean a larva of an insect belonging to the genus Coleoptera.
본 명세서에서 사용하는 용어‘기능’은 인체에 유익한 영향을 미치는 일체의 구실 또는 작용을 의미할 수 있다.As used herein, the term " function " may mean any act or action that has a beneficial effect on the human body.
본 명세서에서 사용하는 용어‘풍미’는 음식 고유의 맛을 의미할 수 있다.As used herein, the term " flavor " may mean a flavor inherent in the food.
본 명세서에서 사용하는 용어‘침지(浸漬)’는 특정 대상을 액체에 담가 적시는 일체의 행위를 의미할 수 있다.As used herein, the term " immersion " may refer to any act of immersing and wetting a particular object in a liquid.
본 발명의 조성물은 생체에 투여되어 면역을 강화하는 작용을 한다.The composition of the present invention is administered to a living body to enhance immunity.
본 명세서에서 사용하는 용어 “면역강화”는 생체내 면역시스템의 면역 반응 또는 활성을 증가시키는 것을 의미할 수 있다.The term " immunologically enhancing ", as used herein, may mean increasing the immune response or activity of an in vivo immune system.
생체 내 면역 반응은 크게 Th1 면역반응 및 Th2 면역반응으로 나눌 수 있다. 본 명세서에서 사용하는 용어 “Th1 면역반응”은 세포면역반응을 유도하는 반응을 의미하고, “Th2 면역반응”은 체액면역반응을 촉진하는 반응을 의미할 수 있다.The in vivo immune response can be divided into Th1 immune response and Th2 immune response. As used herein, the term "Th1 immune response" refers to a reaction that induces a cellular immune response, and "Th2 immune response" may refer to a response that promotes a humoral immune response.
본 발명의 바람직한 양태에 따르면, 본 발명의 조성물은 Th1 면역반응 또는 Th2 면역반응을 증진시킨다. 보다 바람직하게는, 본 발명의 조성물은 Th1 면역반응과 Th2 면역반응 모두를 증진시킨다.According to a preferred embodiment of the present invention, the composition of the present invention promotes a Th1 immune response or a Th2 immune response. More preferably, the compositions of the present invention promote both Th1 and Th2 immune responses.
본 발명의 조성물은 Th1 면역반응에 관여하는 다양한 사이토카인의 발현을 촉진시킨다. 예를 들어, 본 발명의 조성물은 인터루킨-17(IL-17), 인터페론 감마(IFN-?) 또는 종양괴사인자-?(TNF-?)의 발현을 증진시킨다. 본 발명의 조성물은 Th2 면역반응에 관여하는 다양한 사이토카인의 발현을 촉진시킨다. 예를 들어, 본 발명의 조성물은 IL-4 또는 IL-13의 발현을 증진시킨다.The composition of the present invention promotes the expression of various cytokines involved in the Th1 immune response. For example, the compositions of the present invention enhance the expression of interleukin-17 (IL-17), interferon gamma (IFN-?) Or tumor necrosis factor (TNF-?). The composition of the present invention promotes the expression of various cytokines involved in the Th2 immune response. For example, the composition of the present invention enhances the expression of IL-4 or IL-13.
본 발명의 바람직한 양태에 따르면, 본 발명의 조성물은 B 세포, T 세포 또는 B 세포와 T 세포의 증식을 증진시키는 뛰어난 효과를 나타낸다.According to a preferred embodiment of the present invention, the composition of the present invention exhibits an excellent effect of promoting proliferation of B cells, T cells or B cells and T cells.
본 발명의 바람직한 양태에 따르면, 본 발명의 전복 내장 추출물은 B 세포의 IgG(Immunoglobulin G) 또는 IgE(Immunoglobulin E) 항체의 생성을 증가시킨다. IgG는 인체 내에 가장 다량으로 존재하는 항체로서 세균 및 바이러스의 침입시 탐식반응(phagocytosis)을 유도하여 이러한 독성물질의 제거하는 기능을 담당하고 있다. IgE는 특히 기생충의 감염으로부터 우리 몸을 보호하는 중요한 기능을 수행하는 항체의 한 종류이다. 이러한 IgE 역시 기생충의 감염 시 다량 분비되어 면역세포의 탐식반응을 활성화 시켜 감염 세포 및 기생충의 제거를 유도한다.According to a preferred embodiment of the present invention, the overturned extract of the present invention increases the production of IgG (Immunoglobulin G) or IgE (Immunoglobulin E) antibody of B cells. IgG is the most abundant antibody in the human body. It is responsible for the phagocytosis of bacteria and viruses. IgE is a type of antibody that performs an important function to protect our body, especially from infections of parasites. These IgEs are also secreted in large amounts during infection with parasites, thereby activating the immune cell phagocytosis, leading to the elimination of infected cells and parasites.
본 발명에서 흰점박이꽃무지 유충을 아세트산이 포함된 침지액에 침지한 후 숙성하는 구성은 매우 중요한 구성이다. 왜냐하면 흰점박이꽃무지 유충을 아세트산이 포함된 침지액에 침지하여 일정기간 숙성시킬 경우 흰점박이꽃무지 유충에 포함된 미량의 독소를 제거하고, 이취를 제거하여 풍미를 증가시킬 수 있는 것은 물론, 아세트산이 포함된 침지액에 침지하는 과정을 통해 흰점박이꽃무지 유충에 포함된 다수의 유효 성분이 아세트산의 산화 과정에 의해 인체에 보다 쉽게 흡수될 수 있는 물질로 변하여 흰점박이꽃무지 유충 특유의 약효를 증가시킬 수 있기 때문이다.In the present invention, the composition for immersing the white spotted moth larva in an immersion liquid containing acetic acid and aging is a very important constitution. This is because when the white spotted flower larva is immersed in an immersion liquid containing acetic acid and aged for a certain period of time, it is possible to remove a trace amount of toxins contained in the white spotted flower larva and remove the offensive odor, , The active ingredients contained in the white spotted spider mite larvae transformed into a substance that can be easily absorbed by the oxidation process of acetic acid. Thus, the unique effect of the white spotted spider mite larvae As shown in Fig.
본 발명의 바람직한 양태에 따르면, 본 발명의 상기 흰점박이꽃무지 유충은 바람직하게는 세척된 흰점박이꽃무지 유충일 수 있고, 보다 바람직하게는 세척 및 멸균된 흰점박이꽃무지 유충일 수 있으며, 가장 바람직하게는 세척, 멸균 및 건조된 흰점박이꽃무지 유충일 수 있다.According to a preferred embodiment of the present invention, the white spotted flower larva of the present invention can be preferably a washed white spotted flower inflorescence, more preferably a washed and sterilized white spotted flower inflorescence, May be washed, sterilized and dried white spotted flowers.
본 발명에서 세척, 멸균 및 건조된 흰점박이꽃무지 유충을 사용하는 것은 매우 중요한 구성이다. 왜냐하면 흰점박이꽃무지 유충의 멸균 및 건조 처리를 통해 흰점박이꽃무지 유충을 섭취하는 과정에서 발생할 수 있는 이취를 감소시킬 수 있기 때문이다.The use of washed, sterilized and dried white spotted flower larvae in the present invention is a very important constitution. This is because sterilization and drying treatment of white spider mite larvae can reduce the odor that may occur during the intake of white mite spider mite larvae.
본 발명의 바람직한 양태에 따르면, 본 발명의 상기 아세트산이 포함된 침지액은 바람직하게는 식초일 수 있고, 보다 바람직하게는 양조식초일 수 있으며, 보다 더 바람직하게는 과일식초 또는 곡물식초일 수 있으며, 가장 바람직하게는 과일식초일 수 있다.According to a preferred embodiment of the present invention, the acetic acid-containing immersion liquid of the present invention may preferably be vinegar, more preferably be a brewed vinegar, more preferably fruit vinegar or cereal vinegar , And most preferably fruit vinegar.
본 발명에서 흰점박이꽃무지 유충을 과일식초에 침지하여 숙성하는 것은 매우 중요한 구성이다. 왜냐하면 흰점박이꽃무지 유충을 과일식초에 침지하여 일정기간 숙성시킬 경우 과일식초 이외의 다른 식초를 이용하여 숙성시킨 경우와 비교하여 유충 추출물의 풍미를 유의적으로 증가시킬 수 있기 때문이다.In the present invention, it is very important to immerse the white spotted flower larva in fruit vinegar and mature. This is because when the white spider mite larvae are dipped in fruit vinegar and aged for a certain period of time, the flavor of the larvae extract can be significantly increased compared to the case of vinegar other than fruit vinegar.
본 발명의 바람직한 양태에 따르면, 본 발명의 상기 식초의 pH는 바람직하게는 2.0-5.0일 수 있고, 보다 바람직하게는 2.5-4.0일 수 있으며, 가장 바람직하게는 2.7-3.3일 수 있다.According to a preferred embodiment of the present invention, the pH of the vinegar of the present invention may be preferably 2.0-5.0, more preferably 2.5-4.0, and most preferably 2.7-3.3.
상기 식초의 pH가 2.0 미만일 경우 흰점박이꽃무지 유충의 기능성이 소멸되고, 숙성 과정에서 독성이 생성될 수 있는 문제가 있고, 상기 식초의 pH가 5.0을 초과하는 경우 숙성 과정에서 흰점박이꽃무지 유충이 변질될 수 있는 문제가 존재한다.When the pH of the vinegar is less than 2.0, there is a problem that the functionality of the white spider mite larva is extinguished and toxicity can be generated during the aging process. When the pH of the vinegar exceeds 5.0, the white spider mite larva There is a problem that can be altered.
본 발명의 바람직한 양태에 따르면, 본 발명의 상기 식초는 상기 식초 100 중량부를 기준으로 바람직하게는 1 중량부 내지 30 중량부, 보다 바람직하게는 3 중량부 내지 20 중량부, 가장 바람직하게는 5 중량부 내지 10 중량부의 꿀이 추가적으로 혼합될 수 있다.According to a preferred embodiment of the present invention, the vinegar of the present invention is preferably added in an amount of 1 part by weight to 30 parts by weight, more preferably 3 parts by weight to 20 parts by weight, most preferably 5 parts by weight To 10 parts by weight of honey may be further mixed.
본 발명의 바람직한 양태에 따르면, 본 발명의 상기 숙성 시 숙성 온도는 바람직하게는 1-15일 수 있다.According to a preferred embodiment of the present invention, the aging temperature at the aging of the present invention may be preferably 1-15.
상기 숙성 온도가 1 미만일 경우 이취 제거 및 기능성 증가 효과가 미미할 수 있는 문제가 있고, 상기 숙성 온도가 15를 초과할 경우 숙성 과정에서 흰점박이꽃무지 유충이 변질될 수 있는 문제가 존재한다.If the aging temperature is less than 1, there is a problem that the effect of removing odor and improving the functionality may be insignificant. If the aging temperature is more than 15, there is a problem that the white spotted moth larva may be altered during aging.
본 발명의 바람직한 양태에 따르면, 본 발명의 상기 숙성 시 숙성 기간은 바람직하게는 5-20 일일 수 있다.According to a preferred embodiment of the present invention, the aging period of the aging of the present invention may be preferably 5-20 days.
상기 숙성 기간이 5 일 미만일 경우 이취 제거 및 기능성 증가 효과가 미미할 수 있는 문제가 있고, 상기 숙성 기간이 20 일을 초과할 경우 숙성 과정에서 흰점박이꽃무지 유충의 신맛이 증가하여 풍미가 감소될 수 있는 문제가 존재한다.If the aging period is less than 5 days, there is a problem that the effect of removing odor and improving the functionality may be insignificant. If the aging period exceeds 20 days, the sour taste of white spotted flower larva will increase and the flavor may be decreased There is a problem.
본 발명의 바람직한 양태에 따르면, 본 발명의 상기 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 포함하는 면역 강화 조성물은 바람직하게는 흰점박이꽃무지 유충 추출물 100 중량부 및 상기 흰점박이꽃무지 유충 추출물 100 중량부를 기준으로 홍삼 추출물 50 중량부 내지 100 중량부 포함할 수 있다.According to a preferred embodiment of the present invention, the immunity enhancing composition comprising the white spotted moth larva extract and the red ginseng extract of the present invention is preferably prepared by mixing 100 parts by weight of the white spotted moth larva extract and 100 parts by weight of the white spotted moth larva extract And 50 parts by weight to 100 parts by weight of the red ginseng extract.
본 발명의 바람직한 양태에 따르면, 본 발명의 상기 홍삼 추출물은 바람직하게는 건조 홍삼의 파우더일 수 있다.According to a preferred embodiment of the present invention, the red ginseng extract of the present invention is preferably a powder of dried red ginseng.
본 발명에서 상기 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 혼합하는 것은 매우 중요한 구성이다. 왜냐하면 상기 흰점박이꽃무지 유충 추출물에 홍삼 추출물을 일정 비율로 혼합할 경우 조성물의 풍미를 증가시킬 수 있는 것은 물론, 면역력 증강 효과 층면에서도 시너지 효과를 나타낼 수 있기 때문이다.In the present invention, it is a very important constitution to mix the white spotted moth larvae extract and the red ginseng extract. This is because when the red ginseng extract is mixed with the white spotted moth larva extract at a certain ratio, the flavor of the composition can be increased and the synergy effect can be exhibited even in the layer of the immunity enhancing effect.
본 명세서에서 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 언급하면서 사용되는 용어 “추출물”은 상기 흰점박이꽃무지 유충 또는 홍삼 자체를 섭취할 수 있도록 제형화(예컨대, 분말화)한 가공물뿐만 아니라 상기 흰점박이꽃무지 유충 또는 홍삼에 추출용매를 처리하여 얻은 추출 결과물도 포함하는 의미를 갖는다.The term " extract " used herein to refer to the white spotted moth larvae extract and the red ginseng extract in the present specification refers not only to the formulated (for example, pulverized) workpiece so that the white spotted moth larva or red ginseng itself can be ingested, And also includes extraction results obtained by treating the spotted larva or red ginseng with an extraction solvent.
만일, 본 발명의 조성물에서 이용되는 추출물을 상기 유충에 추출용매를 처리하여 얻는 경우에는, 다양한 추출용매가 이용될 수 있다. 바람직하게는, (a) 물, (b) 탄소수 1-4의 무수 또는 함수 저급 알코올 (예: 메탄올, 에탄올, 프로판올, 부탄올, 노말-프로판올, 이소-프로판올 및 노말-부탄올 등), (c) 상기 저급 알코올과 물과의 혼합용매, (d) 아세톤, (e) 에틸 아세테이트, (f) 클로로포름, (g) 1,3-부틸렌글리콜, (h) 헥산, (i) 디에틸에테르, 또는 (j) 부틸아세테이트를 식물에 처리하여 추출물을 얻을 수 있다. If the extract used in the composition of the present invention is obtained by treating the larva with an extraction solvent, various extraction solvents may be used. (B) an anhydrous or a lower alcohol having 1 to 4 carbon atoms such as methanol, ethanol, propanol, butanol, n-propanol, iso-propanol and n-butanol, (E) ethyl acetate, (f) chloroform, (g) 1,3-butylene glycol, (h) hexane, (i) diethyl ether, or (iii) a mixed solvent of a lower alcohol and water. (j) The extract can be obtained by treating the plant with butyl acetate.
본 명세서에서 사용되는 용어 “추출물”은 상술한 바와 같이 당업계에서 조추출물(crude extract)로 통용되는 의미를 갖지만, 광의적으로는 추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다. 즉, 유충 추출물은 상술한 추출용매를 이용하여 얻은 것뿐만 아니라, 여기에 정제과정을 추가적으로 적용하여 얻은 것도 포함한다. 예컨대, 상기 추출물을 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 얻은 분획, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 유충 추출물에 포함되는 것이다.As used herein, the term " extract " has the meaning conventionally used in the art as a crude extract, but broadly includes fractions obtained by further fractionation of the extract. That is, the larvae extract includes not only those obtained using the above-mentioned extraction solvent but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the above extract through an ultrafiltration membrane having a constant molecular weight cut-off value, and a separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) The fraction obtained by the purification method is also included in the larvae extract of the present invention.
본 발명의 바람직한 양태에 따르면, 본 발명의 추출물은 약제학적 조성물일 수 있다.According to a preferred embodiment of the present invention, the extract of the present invention may be a pharmaceutical composition.
본 발명의 추출물이 약제학적 조성물로 제조되는 경우, 본 발명의 약제학적 조성물은 약제학적으로 허용되는 담체를 포함한다. 본 발명의 약제학적 조성물에 포함되는 약제학적으로 허용되는 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약제학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제등을 추가로 포함할 수 있다. 적합한 약제학적으로 허용되는 담체 및 제제는 Remington's Pharmaceutical Sciences (19th ed., 1995)에 상세히 기재되어 있다.When the extract of the present invention is prepared from a pharmaceutical composition, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier. The pharmaceutically acceptable carriers to be contained in the pharmaceutical composition of the present invention are those conventionally used in the formulation and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약제학적 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 경구 또는 비경구 등의 다양한 경로로 투여할 수 있으며, 예컨대 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 주사에 의해 투여할 수 있다. 바람직하게는 비경구 투여 중 경피투여, 보다 바람직하게는 도포에 의한 국부 투여(topical application) 방식으로 적용된다.The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, and humans in various routes such as oral or parenteral routes such as oral, rectal or intravenous, muscular, subcutaneous, intra-uterine, Can be administered by injection. Preferably, it is applied by transdermal administration during parenteral administration, more preferably by topical application by application.
본 발명의 약제학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. 본 발명의 약제학적 조성물의 투여량은, 경구형 제형인 경우 성인 기준으로 0.1-100 ㎎/kg 의 양을 1일 1회 내지 수회 투여할 수 있으며, 외용제인 경우에는 성인 기준으로 1일당 1.0 내지 3.0 ml의 양으로 1일 1 내지 5회 도포하여 1개월 이상 계속 하는 것이 좋다. 다만, 상기 투여량은 본 발명의 범위를 한정하는 것은 아니다.The appropriate dosage of the pharmaceutical composition of the present invention may vary depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate, . The dose of the pharmaceutical composition of the present invention can be administered in an amount of 0.1-100 mg / kg on an adult basis once or several times a day in the case of an oral formulation, and in the case of an external preparation, It is preferable to apply it once to 5 times a day in an amount of 3.0 ml and continue for 1 month or longer. However, the dosage is not intended to limit the scope of the present invention.
본 발명의 약제학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 산제, 과립제, 정제, 캅셀제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 연고, 크림 등의 외용제, 좌제 및 멸균 주사용액 등을 비롯하여 약제학적 제제에 적합한 어떠한 형태로든 사용할 수 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container. The formulations may be in any form suitable for pharmaceutical preparations including oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, external preparations such as ointments and creams, suppositories and sterile injectable solutions, , Dispersants, or stabilizers.
본 발명의 바람직한 양태에 따르면, 본 발명의 추출물은 식품 조성물일 수 있다.According to a preferred embodiment of the present invention, the extract of the present invention may be a food composition.
본 발명의 추출물이 식품 조성물로 제조되는 경우, 유효성분뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다.When the extract of the present invention is prepared with a food composition, it includes not only the active ingredient, but also ingredients normally added during the manufacture of the food, for example, proteins, carbohydrates, fats, nutrients, flavoring agents and flavoring agents . Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings.
예컨대, 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 본 발명의 유효성분 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다.For example, when the food composition of the present invention is prepared as a drink, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract and licorice extract may be further added in addition to the active ingredient of the present invention have.
본 발명의 바람직한 양태에 따르면, 본 발명의 추출물은 화장료 조성물일 수 있다.According to a preferred embodiment of the present invention, the extract of the present invention may be a cosmetic composition.
본 발명의 실시예에 따르면, 본 발명의 화장료 조성물은 글리세린, 부틸렌 글라이콜, 폴리옥시에칠렌 경화피마자유, 토코페릴 아세테이트, 시트릭산, 판테놀, 스쿠알란, 소듐 시트레이트 및 알란토인으로 포함된 군으로부터 선택되는 최소 하나의 보조성분을 추가적으로 포함하며, 보다 바람직하게는 글리세린, 폴리옥시에칠렌 경화피마자유, 토코페릴 아세테이트, 스쿠알란 및 소듐 시트레이트을 추가적으로 포함하고, 부틸렌 글라이콜, 시트릭산, 판테놀 및 알란토인으로 구성된 군으로부터 선택되는 최소 하나의 성분을 포함하며, 가장 바람직하게는 글리세린, 부틸렌 글라이콜, 폴리옥시에칠렌 경화피마자유, 토코페릴 아세테이트, 시트릭산, 판테놀, 스쿠알란, 소듐 시트레이트 및 알란토인 모두를 추가적으로 포함한다.According to an embodiment of the present invention, the cosmetic composition of the present invention is obtained from the group comprising glycerin, butylene glycol, polyoxyethylene hydrogenated castor oil, tocopheryl acetate, citric acid, panthenol, squalane, sodium citrate and allantoin Further comprising at least one auxiliary component selected from the group consisting of glycerin, polyoxyethylene hydrogenated castor oil, tocopheryl acetate, squalane and sodium citrate, and at least one auxiliary ingredient selected from the group consisting of butylene glycol, citric acid, panthenol and allantoin And most preferably at least one component selected from the group consisting of glycerin, butylene glycol, polyoxyethylene hydrogenated castor oil, tocopheryl acetate, citric acid, panthenol, squalane, sodium citrate and allantoin .
본 발명의 화장료 조성물은 기본적으로 피부에 도포되는 것이므로, 당업계의 화장료 조성물을 참조하여 제공될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.Since the cosmetic composition of the present invention is basically applied to the skin, it can be provided with reference to the cosmetic composition of the related art, for example, as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, But are not limited to, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations and sprays. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올, 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가, 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Crystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.
한편, 본 발명의 구체적 실시예에서 본 발명 조성물의 유효성분에 대한 세포 생존율 분석 결과 본 발명 조성물의 유효성분은 천연물질로서 인체에 무해한 물질임이 밝혀졌다. 따라서, 본 발명의 유효성분은 독성 및 부작용이 거의 없으므로 장기간 사용 시에도 안심하고 사용할 수 있으며, 특히 상기한 바와 같은 화장료, 약제학적 및 식품 조성물에 안전하게 적용할 수 있다.
As a result of analyzing cell viability with respect to the active ingredient of the composition of the present invention in the concrete examples of the present invention, it was found that the active ingredient of the composition of the present invention is a harmless substance as a natural substance. Therefore, since the active ingredient of the present invention has little toxicity and side effects, it can be safely used even for long-term use, and can be safely applied to cosmetic, pharmaceutical and food compositions as described above.
본 발명의 특징 및 이점을 요약하면 다음과 같다: The features and advantages of the present invention are summarized as follows:
(a) 본 발명은 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 유효성분으로 포함하되, 상기 흰점박이꽃무지 유충 추출물은 흰점박이꽃무지 유충을 아세트산이 포함된 침지액에 침지한 후 숙성하여 숙성된 유충을 제조한 후, 상기 숙성된 유충을 건조 및 분쇄하여 제조되는 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 포함하는 면역 강화 조성물을 제공한다.(a) The present invention includes a white spotted moth larvae extract and a red ginseng extract as an active ingredient, wherein the white spotted moth larva extract is obtained by immersing the white spotted moth larva in an immersion liquid containing acetic acid, The present invention provides an immunity enhancing composition comprising a white spotted flower larva and a red ginseng extract prepared by drying and pulverizing the aged larva after producing the larva.
(b) 본 발명의 조성물은 흰점박이꽃무지 유충 특유의 이취를 제거하여 흰점박이꽃무지 유충의 식품 사용 가능성을 높일 수 있는 것은 물론, 흰점박이꽃무지 유충 고유의 독성은 없애고, 면역력 강화 효과는 높일 수 있는 장점을 제공한다.
(b) The composition of the present invention can remove the odor of white spotted flower larvae, thereby increasing the possibility of using food of white spotted flower larvae, eliminating inherent toxicity of white spotted flower larvae and enhancing immunity It also provides the advantage that it can increase.
도 1은 본 발명의 혼합 추출물이 포함된 조성물의 모습을 나타낸다.BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows a composition comprising a mixed extract of the present invention.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명 하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 요지 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not to be construed as limiting the scope of the present invention. It will be self-evident.
실시예Example
본 명세서 전체에 걸쳐, 특정 물질의 농도를 나타내기 위하여 사용되는 “%“는 별도의 언급이 없는 경우, 고체/고체는 (중량/중량) %, 고체/액체는 (중량/부피) %, 그리고 액체/액체는 (부피/부피) %이다.
Throughout this specification, "%" used to denote the concentration of a particular substance is intended to include solids / solids (wt / wt), solid / liquid (wt / The liquid / liquid is (vol / vol)%.
제조예Manufacturing example
사육예 : 흰점박이꽃무지 유충의 사육Breeding Example: Breeding of white spotted flowers larvae
흰점박이꽃무지 유충은 스머프 곤충나라 영농조합법인(남양주시)에서 구매한 3령 유충을 사용하였으며, 사육온도는 25를 유지하였다. 흰점박이꽃무지 유충의 사육환경은 40 ㎝(가로) × 30 ㎝(세로) × 20 ㎝(높이) 크기의 투명한 곤충사육용기를 이용하여 용기의 2/3정도를 약 60~65%의 수분이 함유된 참나무 발효톱밥을 채운 후 유충을 20마리씩 사육하였다.
White spider mite larvae were used for the third instar larvae purchased from the Smurf Insect Country Farmers Union (Namyangju City) and maintained the breeding temperature at 25. The environment of white spotted larvae larvae is about 60 ~ 65% of moisture in about two thirds of container using transparent insect rearing container of 40 ㎝ (width) × 30 ㎝ (length) × 20 ㎝ (height) The oak fermented sawdust was filled and 20 larvae were raised.
제조예 2 : 흰점박이꽃무지 유충 추출물의 제조Preparation Example 2: Preparation of white spotted moth larvae extract
제조예 2-1 : 식초 숙성 흰점박이꽃무지 유충의 제조Production Example 2-1: Preparation of vinegar-ripening white spotted flower larva
상기 사육예의 방식으로 사육한 흰점박이꽃무지 유충을 3일 동안 굶긴 후, 액체질소로 급속 동결시키고, -80의 초저온 냉동고에서 24시간 동안 동결시킨 다음 동결 건조기에서 수분이 완전히 제거될 때까지 건조시켰다. 동결건조된 흰점박이꽃무지 유충을 매실식초 100 중량부 및 상기 매실식초 100 중량부를 기준으로 5 중량부의 꿀을 포함하는 혼합액에 침지한 후 5에서 10일간 숙성시켜 식초 숙성 흰점박이꽃무지 유충을 제조하였다.
The white spotted caterpillars raised in the above-mentioned breeding mode were starved for 3 days, rapidly frozen in liquid nitrogen, frozen in a -80 cryocooler for 24 hours, and then dried in a freeze dryer until the water was completely removed . The lyophilized white spotted flower larvae were immersed in a mixture of 100 parts by weight of plum vinegar and 5 parts by weight of honey on the basis of 100 parts by weight of the plum vinegar and aged for 5 to 10 days to prepare vinegar aged white spotted flower larva Respectively.
제조예 2-2 : 흰점박이꽃무지 유충 파우더의 제조Production Example 2-2: Preparation of white spotted flower larvae powder
상기 제조예 2-2의 방법으로 제조한 식초 숙성 흰점박이꽃무지 유충을 동결 건조기에서 수분이 완전히 제거될 때까지 건조시킨 후 분쇄하여 비교예 1의 흰점박이꽃무지 유충 파우더를 제조하였다.
The vinegar ripened white spotted flower larvae prepared by the method of Preparation Example 2-2 were dried in a freeze drier until the water was completely removed and pulverized to prepare white spotted flower larvae of Comparative Example 1.
제조예 3 : 홍삼 추출물의 제조Preparation Example 3: Preparation of red ginseng extract
홍삼을 동결 건조기에서 수분이 완전히 제거될 때까지 건조시킨 후 분쇄하여 비교예 2의 홍삼 파우더를 제조하였다.
The red ginseng was dried and pulverized in a freeze dryer until the water was completely removed to prepare the red ginseng powder of Comparative Example 2.
제조예 4 : 혼합 추출물의 제조Preparation Example 4: Preparation of mixed extract
제조예 4-1 혼합 추출물의 제조Production Example 4-1 Preparation of mixed extract
상기 제조예 2-1의 방법으로 제조한 흰점박이꽃무지 유충 파우더 100 중량부 및 상기 흰점박이꽃무지 유충 파우더 100 중량부를 기준으로 상기 제조예 3의 방법으로 제조한 홍삼 파우더 100 중량부를 혼합하여 실시예 1의 혼합 추출물을 제조하였다. 비교예 혼합 추출물은 상기 사육예의 방식으로 사육한 흰점박이꽃무지 유충을 3일 동안 굶긴 후, 액체질소로 급속 동결시키고, -80의 초저온 냉동고에서 24시간 동안 동결시킨 다음 동결 건조기에서 수분이 완전히 제거될 때까지 건조시킨 후 분쇄하여 비교예 흰점박이꽃무지 유충 파우더를 제조하고, 상기 비교예 흰점박이꽃무지 유충 파우더 100 중량부 및 상기 비교예 흰점박이꽃무지 유충 파우더 100 중량부를 기준으로 상기 제조예 3의 방법으로 제조한 홍삼 파우더 100 중량부를 혼합하여 비교예 3의 혼합 추출물을 제조하였다.
100 parts by weight of the white spotted flower larvae powder prepared by the method of Production Example 2-1 and 100 parts by weight of the red spotted powder obtained by the method of Preparation Example 3 were mixed with 100 parts by weight of the white spotted flower larvae powder The mixed extract of Example 1 was prepared. The comparative mixed extract was prepared by starving the white spotted flower larvae raised in the above-mentioned manner, rapidly frozen in liquid nitrogen, frozen in a -80 cryocooler for 24 hours, and then completely free of moisture in the freeze dryer Dried and pulverized to prepare a comparative white spotted flower larvae powder. 100 parts by weight of the comparative white spotted flower larvae powder and 100 parts by weight of the comparative white spotted flower larvae powder of Comparative Example 3 was mixed with 100 parts by weight of red ginseng powder to prepare a mixed extract of Comparative Example 3.
제조예 4-1 : 혼합 추출물 현탁액의 제조Production Example 4-1: Preparation of Mixed Extract Suspension
상기 실시예 1 및 비교예 3의 혼합 추출물 1 g을 증류수(D.W.) 1L에 넣은 후, 초음파 분쇄기 230줄(Jule)로 10초간 2회 미세화시켰다. 초음파 분쇄기로 미세화시킨 혼합 추출물 혼합액을 4,500 rpm에서 10분 동안 원심분리 시키고, 상층액을 회수한 후 0.25 ㎛ 주사기 필터로 여과하여, 실시예 2 및 비교예 4의 혼합 추출물 현탁액(증류수)을 제조하였다.
1 g of the mixed extract of Example 1 and Comparative Example 3 was put into 1 L of distilled water (DW), and then refined twice for 10 seconds with 230 ultrasonic pulverizers (Jule). The mixed extract mixture obtained by micronization with an ultrasonic pulverizer was centrifuged at 4,500 rpm for 10 minutes, and the supernatant was recovered and filtered with a 0.25 mu m syringe filter to prepare a mixed extract suspension (distilled water) of Example 2 and Comparative Example 4 .
실험예Experimental Example
실험예 1 : 흰점박이꽃무지 유충 추출물의 독성평가Experimental Example 1: Evaluation of Toxicity of White Spotted Flower Larvae
흰점박이꽃무지의 대식세포인 Raw 264.7에 대한 독성 효과를 측정하기 위해 세포에 흰점박이꽃무지 유충 현탁액을 각각 처리하고 24 시간 경과한 시점에 MTS {3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2- (4-sulfophenyl)-2H-tetrazolium } 시약을 넣고 36에서 4시간 더 배양하였다. 배양 후 microplate reader(Beckman, USA)를 이용하여 450 nm에서 흡광도를 측정하였다. 그 결과 상기 비교예 4의 혼합 추출물 현탁액에서 경미한 독성이 검출되었으나, 상기 실시예 2의 혼합 추출물 현탁액의 경우 세포독성이 전혀 검출되지 않았다.
To measure the toxic effect of Raw 264.7, a macrophage of white spotted flowers, on the cells, each of the cells was treated with a suspension of the white spotted larva larvae. After 24 hours, MTS {3- (4,5-dimethylthiazol-2-yl ) -5 (3-carboxymethonyphenol) -2- (4-sulfophenyl) -2H-tetrazolium reagent. After incubation, absorbance was measured at 450 nm using a microplate reader (Beckman, USA). As a result, slight toxicity was detected in the mixed extract suspension of Comparative Example 4, but no cytotoxicity was detected in the mixed extract suspension of Example 2.
실험예 2 : 흰점박이꽃무지 유충 추출물의 면역력 강화 효과Experimental Example 2: Immunity enhancement effect of white spotted moth larvae extract
실험예 2-1 : T 세포와 B 세포의 분리Experimental Example 2-1: Isolation of T cells and B cells
두 그룹의 마우스에게 PBS 또는 실시예 2의 현탁액을 20일간 구강 투여한 뒤 각각의 마우스에서 비장과 장 림프절을 적출하였다. 이렇게 적출한 림프절을 콜라게나아제 V(collagenase V; Sigma, 미국)를 이용하여 단일세포 수준으로 만들었다. 단일세포로부터 T 세포와 B 세포의 특이적 분리를 위해 T 세포는 CD4+ 분리 마그네틱 비즈(isolation magnetic beads; Milteny Biotech, 독일, Cat No.130-049-201), B 세포는 B220 마그네틱 비즈(Milteny Biotech, 독일)를 사용하고, 컬럼(columns; Milteny Biotech, 독일, Cat No. 130-042-401)은 사용하여 림프절 T 세포와 B 세포를 획득하였다.
Two groups of mice were orally administered with PBS or the suspension of Example 2 for 20 days, and the spleen and intestinal lymph nodes were excised from each mouse. These extracted lymph nodes were made into single cell levels using collagenase V (Sigma, USA). T cells were isolated from CD4 + isolation magnetic beads (Milteny Biotech, Germany, Cat No. 130-049-201) and B cells were cultured with B220 magnetic beads (Milteny Biotech , Germany) and columns (Milteny Biotech, Germany, Cat No. 130-042-401) were used to obtain lymph node T cells and B cells.
실험예 2-2 : 사이토카인 발현의 측정Experimental Example 2-2: Measurement of cytokine expression
T 세포와 B 세포가 발현하는 사이토카인의 양의 측정을 위해 분리한 T 및 B 세포로부터 Trizol reagent(Molecular Research center)을 이용하여 RNA를 분리하고, 분리한 RNA 1 ㎍을 oligo(dT) primer(Promega)와 및 Improm-II Reverse Transcription System(Promega)을 이용하여 cDNA를 합성하였다. 이렇게 합성된 cDNA를 이용하여 특정 사이토카인을 특이적으로 증폭시킬 수 있는 다양한 프라이머를 이용해 정량적 실시간 중합효소연쇄반응(quantitative real-time PCR)을 사용하여 각 세포가 발현하고 있는 사이토카인의 양의 정량적으로 분석하였다. RNA was isolated from T and B cells using Trizol reagent (Molecular Research center) for the measurement of the amount of cytokine expressed by T cells and B cells, and 1 μg of the separated RNA was treated with oligo (dT) primer Promega) and Improm-II Reverse Transcription System (Promega). Quantitative real-time PCR was used to quantitatively quantify the amount of cytokine expressed by each cell using various primers capable of specifically amplifying a specific cytokine using the synthesized cDNA. Respectively.
T 세포가 발현하는 사이토카인의 경우 비장 위치 T 세포가 나타내 결과는 전복 내장 추출물의 구강투여가 전체면역에 미치는 영향을 나타내었으며, 장 림프절 위치 T 세포가 나타내는 결과는 정관면역계에 미치는 영향을 나타내는데, 실시예 2의 현탁액을 구강 투여한 마우스 비장위치 T 세포의 경우 IL-4(Interleukin-4), IL-17(Interleukin-17) 및 TNF-?(Tumor Necrosis Factor-?)의 발현정도가 대조군에 비해 의미 있게 증가함을 확인할 수 있었다. 또한, 앞서 비장위치 T 세포와 유사하게 장 림프절 위치 T 세포의 경우도 특이적으로 IL-4와 IL-17의 발현이 의미 있게 높아졌음을 확인할 수 있었으며, 인터페론 감마(Interferon-gamma: IFN-?)의 발현 역시 유의성 있게 증가했음을 확인할 수 있었다.In the case of cytokines expressing T cells, the results of spleen T cells showed the effect of oral administration of Abalone intestinal extract on total immunity. The results of intestinal lymph node T cells showed the influence on the vasculature immune system, The expression level of IL-4 (Interleukin-4), IL-17 (Interleukin-17) and TNF-? (Tumor Necrosis Factor-?) In the mouse spleen position T cells administered with the suspension of Example 2 was compared with that of the control , Respectively. In addition, IL-4 and IL-17 expression was significantly increased in long-lived lymphocyte T cells similar to splenic T cells. Interferon-gamma (IFN-? ) Expression was also significantly increased.
B 세포가 발현하는 사이토카인의 경우 실시예 2 현탁액의 구강투여는 비장위치 B 세포에서 특이적으로 TNF-?의 발현 양을 크게 증가시키는 것을 확인할 수 있었으며, 장 림프절 위치 B 세포에는 IL-13(Interleukin-13)의 발현을 의미 있는 수준으로 증가시킴을 확인할 수 있었다.
In the case of cytokines expressing B cells, oral administration of the suspension of Example 2 markedly increased the amount of TNF-? Expression specifically in spleen B cells. In the case of intestinal lymph node B cells, IL-13 Interleukin-13 expression was significantly increased.
실험예 2-3 : IgG(immunoglobulin G)와 IgE(immunoglobulin E)의 분비능력 측정Experimental Example 2-3: Measurement of secretion ability of IgG (immunoglobulin G) and IgE (immunoglobulin E)
B 세포가 분비하는 항체 양의 측정을 위해 각 마우스에서 분리한 B 세포를 지질다당체(lipopolisaccharide: LPS)(Sigma, 미국), CD40 항체(BD Bioscience, 미국), IgM 항체(BD Bioscience, 미국) 및 IL-4(InterLukin-4; (BD Bioscience, 미국)를 통한 다양한 자극을 준 뒤 총 3일간 배양기에서 배양하였다. 수거한 배양액 내에 존재하는 항체의 양을 정량적으로 분석하기 위해 IgG 항체는 마우스 IgG ELISA(Enzyme-Linked Immunosorbent Assay) 키트(BD Bioscience, 미국)를 이용하고, IgE 항체는 마우스 IgG ELISA 키트(Bethyl Laboratories, Inc., 미국)를 이용하여 배양액에 포함된 IgG와 IgE의 양을 측정하였다.B cells isolated from each mouse were measured for lipopolysaccharide (LPS) (Sigma, USA), CD40 antibody (BD Bioscience, USA), IgM antibody (BD Bioscience, To quantitatively analyze the amount of antibody present in the collected culture medium, the IgG antibody was incubated with a mouse IgG ELISA (Invitrogen) (BD Bioscience, USA) kit, and the amount of IgG and IgE contained in the culture solution was measured using a mouse IgG ELISA kit (Bethyl Laboratories, Inc., USA).
IgG 항체 및 IgE 항체의 양을 측정한 실험에서 실시예 2 현탁액을 섭취한 마우스의 B 세포가 대조군의 B 세포에 비해 매우 높은 수준의 IgG 항체 및 IgE 항체 분비 능력을 가지고 있음을 확인할 수 있었다. 이를 통해 실시예 2 현탁액의 섭취가 B 세포의 항체 생산 능력을 높은 수준으로 증가시키는 것을 확인할 수 있었다.
IgG antibody and IgE antibody, it was confirmed that the B cells of the mice in which the suspension of Example 2 was consumed had a very high level of IgG antibody and IgE antibody secretion ability as compared with the B cells of the control group. Thus, it was confirmed that the ingestion of the suspension of Example 2 increased the antibody production capacity of B cells to a high level.
실험예 3 : 흰점박이꽃무지 유충 추출물의 관능평가Experimental Example 3: Sensory evaluation of larvae of white spotted flowers
기호 평가에서는 상기 실시예 1의 방법으로 제조한 혼합 추출물의 풍미와 후각적 기호를 조사하였으며, (주)보뚜슈퍼푸드에 근무하는 임직원 등 30명을 선정하여 해당 인원을 대상으로 하여 실시하였다. 상기 실시예 1의 방법으로 제조한 흰점박이꽃무지 유충 파우더를 그 대상으로 하여, 시식 후 1에서 10까지 10단계로 제조방법 처리구의 기호성을 평가하여 기록하게 하였다. 시식 시에는 실시예 1의 방법으로 제조한 혼합 추출물을 정제수에 10배 희석한 음료 100 mL를 제공하였다. 기호성은 풍미와 후각적 특성 두 가지 요소로 분리하여 시식 및 기록하였다. 비교예로는 상기 비교예 1 내지 비교예 3의 방법으로 제조한 추출물을 정제수에 10배 희석한 음료를 각각 100 mL 씩 제공하였다.In the taste evaluation, the flavor and olfactory taste of the mixed extract prepared by the method of Example 1 above were examined, and 30 persons including employees working at Botou Superfood Co., Ltd. were selected and the subjects were selected. The white spotted flower larvae powder prepared by the method of Example 1 was evaluated and the palatability of the treatment method was evaluated by 10 steps from 1 to 10 after the test. At the time of sampling, the mixed extract prepared by the method of Example 1 was diluted 10 times with purified water to give 100 mL of beverage. Palatability was tasted and recorded by two factors, flavor and olfactory. As a comparative example, the extracts prepared by the methods of Comparative Examples 1 to 3 were diluted 10-fold in purified water to give 100 mL of each of the beverages.
실험 결과, 하기 표 1에서 확인할 수 있는 바와 같이 풍미와 후각적 특성 두 측면의 답변 모두에서 실시예 1에 해당하는 시료가 가장 높은 선호도를 얻어냈으며, 그 수치에 있어서도 비교예와 비교하여 현저하게 우수한 결과를 나타냈다. 위 결과를 바탕으로 판단하였을 때 본 발명에서 제시하는 제조 방법으로 제조한 혼합 추출물의 풍미 및 후각적 기호성이 다른 제조 방법에 의한 것에 비하여 월등히 향상되었음을 확인할 수 있었다. As a result of the experiment, as shown in the following Table 1, the samples corresponding to the Example 1 obtained the highest preference in both answers to the two aspects of flavor and olfactory characteristics, Results are shown. Based on the above results, it was confirmed that the flavor and olfactory palatability of the mixed extract prepared according to the present invention were significantly improved as compared with those of other production methods.
각 항목별 상단칸은 평균값, 하단칸은 그 표준편차
The upper column for each item is the average value, and the lower column is the standard deviation
Claims (10)
상기 흰점박이꽃무지 유충 추출물은 흰점박이꽃무지 유충을 아세트산이 포함된 침지액에 침지한 후 숙성하여 숙성된 유충을 제조한 후, 상기 숙성된 유충을 건조 및 분쇄하여 제조되는 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 포함하는 면역 강화 조성물.
White spotted spider mite larvae extract and red ginseng extract as active ingredients,
The white spotted moth larva extract is prepared by immersing a white spotted moth larva in an immersion liquid containing acetic acid and then aging to prepare an aged larva. The mature larva is then dried and pulverized to obtain a white spotted spotted larva An extract and a red ginseng extract.
상기 흰점박이꽃무지 유충은 건조된 것을 특징으로 하는 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 포함하는 면역 강화 조성물.
The method according to claim 1,
Wherein the white spotted flower larva is dried, and wherein the white spotted flower larva extract and the red ginseng extract are dried.
상기 아세트산이 포함된 침지액은 식초인 것을 특징으로 하는 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 포함하는 면역 강화 조성물.
The method according to claim 1,
Wherein the immersion liquid containing acetic acid is a vinegar, and the immune enhancing composition comprises a white spotted moth larva extract and a red ginseng extract.
상기 식초는 과일 또는 곡물을 발효하여 제조한 과일식초 또는 곡물식초인 것을 특징으로 하는 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 포함하는 면역 강화 조성물.
The method of claim 3,
Wherein the vinegar is a fruit vinegar or a cereal vinegar prepared by fermenting fruits or cereals.
상기 식초의 pH는 2.5-4.0인 것을 특징으로 하는 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 포함하는 면역 강화 조성물.
The method of claim 3,
Wherein the pH of the vinegar is 2.5-4.0. 6. The composition of claim 1, wherein the pH of the vinegar is 2.5-4.0.
상기 식초는 상기 식초 100 중량부를 기준으로 5 중량부 내지 10 중량부의 꿀이 추가적으로 혼합된 것을 특징으로 하는 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 포함하는 면역 강화 조성물.
The method of claim 3,
Wherein the vinegar is further mixed with 5 to 10 parts by weight of honey based on 100 parts by weight of the vinegar.
상기 숙성 시 숙성 온도는 1-15인 것을 특징으로 하는 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 포함하는 면역 강화 조성물.
The method according to claim 1,
Wherein the aging temperature during aging is from about 1 to about 15.
상기 숙성 시 숙성 기간은 5-20 일인 것을 특징으로 하는 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 포함하는 면역 강화 조성물.
The method according to claim 1,
Wherein the aging time is 5-20 days at the time of aging.
상기 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 포함하는 면역 강화 조성물은 흰점박이꽃무지 유충 추출물 100 중량부 및 상기 흰점박이꽃무지 유충 추출물 100 중량부를 기준으로 홍삼 추출물 50 중량부 내지 100 중량부 포함하는 것을 특징으로 하는 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 포함하는 면역 강화 조성물.
The method according to claim 1,
The immunopotentiating composition comprising the white spotted flower larva and the red ginseng extract comprises 50 parts by weight to 100 parts by weight of the red ginseng extract on the basis of 100 parts by weight of the white spotted flower larva extract and 100 parts by weight of the white spotted flower larva extract, Which is characterized in that it comprises a white spotted moth larvae extract and a red ginseng extract.
상기 홍삼 추출물은 건조 홍삼의 파우더인 것을 특징으로 하는 흰점박이꽃무지 유충 추출물 및 홍삼 추출물을 포함하는 면역 강화 조성물.
10. The method of claim 9,
Wherein the red ginseng extract is a powder of dried red ginseng.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160104039A KR20180019839A (en) | 2016-08-17 | 2016-08-17 | Composition for Enhancing Immune System Function Comprising Extract of Protaetia Orientalis Larva and Red Ginseng |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160104039A KR20180019839A (en) | 2016-08-17 | 2016-08-17 | Composition for Enhancing Immune System Function Comprising Extract of Protaetia Orientalis Larva and Red Ginseng |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180019839A true KR20180019839A (en) | 2018-02-27 |
Family
ID=61394452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160104039A KR20180019839A (en) | 2016-08-17 | 2016-08-17 | Composition for Enhancing Immune System Function Comprising Extract of Protaetia Orientalis Larva and Red Ginseng |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20180019839A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200013367A (en) * | 2018-07-30 | 2020-02-07 | 서원대학교산학협력단 | Fermented composition of protaetia brevitarsis seulensis larvae and the preparation method thereof |
| KR20200062024A (en) * | 2018-11-26 | 2020-06-03 | (주)원광허브 | Anti-inflammatory or immunity-boosting composition comprising Protaetia Brevitarsis extract prepared by high pressure-enzymatic hydrolysis system |
| JP2021528429A (en) * | 2018-06-21 | 2021-10-21 | ジーエス カルテックス コーポレイション | Solvent composition for natural substance extraction |
-
2016
- 2016-08-17 KR KR1020160104039A patent/KR20180019839A/en unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021528429A (en) * | 2018-06-21 | 2021-10-21 | ジーエス カルテックス コーポレイション | Solvent composition for natural substance extraction |
| KR20200013367A (en) * | 2018-07-30 | 2020-02-07 | 서원대학교산학협력단 | Fermented composition of protaetia brevitarsis seulensis larvae and the preparation method thereof |
| KR20200062024A (en) * | 2018-11-26 | 2020-06-03 | (주)원광허브 | Anti-inflammatory or immunity-boosting composition comprising Protaetia Brevitarsis extract prepared by high pressure-enzymatic hydrolysis system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6381818B2 (en) | Composition comprising an extract or fraction of a genus Fox | |
| US8518462B2 (en) | Compound comprising extracts or fractions of chrysanthemum boreale makino having anti-inflammation activity | |
| KR20150086982A (en) | Composition comprising Polygala tenuifolia extract for preventing or treating atopic dermatitis | |
| KR20180090937A (en) | Composition of Functional Cosmetic comprising Purified Snake Venom as an Active Ingredient | |
| KR101966315B1 (en) | Composition for Suppressing Immune Responses Using an Extract of Ecklonia cava and an Extract of Sargassum horneri | |
| KR20180019839A (en) | Composition for Enhancing Immune System Function Comprising Extract of Protaetia Orientalis Larva and Red Ginseng | |
| KR101821712B1 (en) | Composition for Preventing, Improving or Treating of Th2-Mediated Immune Disease Comprising Extracts from Panax notoginseug, Saponaria officinalis L. , Glycine max L., Phaseolus radiatus L., Phaseolus vulgaris L. | |
| KR20180019838A (en) | Method of Preparing a Protaetia Orientalis Larva Extract with Enhancing Function and Flavor | |
| KR101538743B1 (en) | Composition for Preventing, Improving or Treating of Ｔｈ1-mediated Immune Disease or Ｔｈ2-mediated Immune Disease Comprising Extracts from Saussurea lappa Clarke and Biota orientalis (L.) Endl. as an Active Ingredients | |
| KR101732031B1 (en) | Composition for Preventing, Improving or Treating of Allergy Disease Comprising Extracts from Illicium religiosum | |
| KR20180019845A (en) | Composition for Treating Hangover Comprising Extract of Protaetia Orientalis Larva and Hovenia Dulcis Fruit | |
| KR101803899B1 (en) | Composition for Improving Atopic Skin Using an Extract of Fermented Green Tea | |
| KR20180019843A (en) | Composition for Antioxidant Function Comprising Extract of Protaetia Orientalis Larva and Aronia | |
| KR101286266B1 (en) | Composition for hair loss prevention and/or hair growth promotion comprising fermented pruni cortex | |
| KR101816739B1 (en) | Composition for preventing or treating inflammatory skin disease | |
| KR20220081301A (en) | Pharmaceutical composition for preventing or treating infalmmatory disease comprising glycyrrhiza glabra l. and orus alba l. | |
| KR101700850B1 (en) | Composition for treating, improving or preventing allergic disease containing extract of Triticum aestivum Lamarck | |
| KR20190019446A (en) | Composition for blocking AGEs production and promoting AGEs decomposition comprising Korthalsella japonica extracts | |
| KR102209969B1 (en) | Composition comprising Fritillariae Thunbergii Bulbs extract for preventing or treating atopic dermatitis | |
| KR101958454B1 (en) | Composition for blocking AGEs production and promoting AGEs decomposition comprising defatted Torreya nucifera's seed extract | |
| KR20180019847A (en) | Composition for Antiobesity Comprising Extract of Protaetia Orientalis Larva and Calamansi | |
| KR102119421B1 (en) | Composition for Anti-Allergy Using an Extract of Catalpa ovata | |
| KR101890220B1 (en) | Composition for preventing, improving and treating atopic dermatitis comprising ginseng berry extract fermented using Hericium erinaceum mycelium as effective component | |
| KR20150087657A (en) | Composition comprising the purified extract of Eriobotrya japonica Radix for immune activity | |
| KR101624293B1 (en) | Composition for enhancing immune response comprising extract of Benincasa hispida Cogniaux or fermented extract of the same |